SCP-776 is under clinical development by Silver Creek Pharmaceuticals and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SCP-776’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SCP-776 is under development for the treatment of congestive heart failure and acute ischemic stroke. It is administered through parenteral and intravenous route. The therapeutic candidates act by targeting the insulin-like growth factor-1 receptor. The therapeutic candidates comprise of protein which is modified by fusing them to insulin-like growth factor-1 and Annexin A5 (AnxV).
Silver Creek Pharmaceuticals overview
Silver Creek Pharmaceuticals (Silver Creek) is a clinical-stage biotechnology that discovers and develops targeted protein therapeutics. The company’s pipeline products include scp776, scp787 and scp791. Its pipeline products therapeutic areas include acute ischemic stroke, cosmetic dermatology applications and Parkinson’s disease. The company designs smart growth factors technology (SGF), a new platform of bio-therapeutics with improved pharmacodynamics, pharmacokinetics and accumulation, improving drug-like properties to optimize as cardioprotective therapeutics. Silver Creek is headquartered in San Francisco, California, the US.
For a complete picture of SCP-776’s drug-specific PTSR and LoA scores, buy the report here.